BioLargo Subsidiary Clyra Medical Advances Product Distribution Through a Series of Agreements
BioLargo (OTCQX:BLGO) announced that its subsidiary Clyra Medical Technologies has secured multiple distribution agreements for its medical products in domestic and international markets. While these agreements don't include minimum purchase requirements, they each have the potential to generate significant revenue for Clyra. CEO Dennis P. Calvert highlighted the company's investment in meeting client specifications and bringing products to market, though no specific timeline or sales volume predictions were provided.
BioLargo (OTCQX:BLGO) ha annunciato che la sua controllata Clyra Medical Technologies ha ottenuto diversi accordi di distribuzione per i suoi prodotti medicali sia nei mercati nazionali che internazionali. Sebbene tali accordi non prevedano requisiti minimi di acquisto, ciascuno di essi potrebbe generare ricavi significativi per Clyra. Il CEO Dennis P. Calvert ha sottolineato l'investimento dell'azienda nel soddisfare le specifiche dei clienti e nel portare i prodotti sul mercato, senza però fornire tempistiche precise o previsioni sulle vendite.
BioLargo (OTCQX:BLGO) anunció que su subsidiaria Clyra Medical Technologies ha asegurado múltiples acuerdos de distribución para sus productos médicos en mercados nacionales e internacionales. Aunque estos acuerdos no incluyen requisitos mínimos de compra, cada uno tiene el potencial de generar ingresos significativos para Clyra. El CEO Dennis P. Calvert destacó la inversión de la compañía en cumplir con las especificaciones de los clientes y llevar los productos al mercado, aunque no se proporcionaron plazos específicos ni predicciones de volumen de ventas.
BioLargo (OTCQX:BLGO)는 자회사 Clyra Medical Technologies가 국내외 시장에서 의료 제품에 대한 다수의 유통 계약을 체결했다고 발표했습니다. 이 계약들은 최소 구매 조건은 포함하지 않지만, 각각이 Clyra에 상당한 수익을 창출할 잠재력을 가지고 있습니다. CEO Dennis P. Calvert는 고객 요구사항을 충족시키고 제품을 시장에 출시하기 위한 회사의 투자를 강조했으나, 구체적인 일정이나 판매량 예측은 제공하지 않았습니다.
BioLargo (OTCQX:BLGO) a annoncé que sa filiale Clyra Medical Technologies a conclu plusieurs accords de distribution pour ses produits médicaux sur les marchés nationaux et internationaux. Bien que ces accords ne comportent pas d'exigences minimales d'achat, chacun d'eux a le potentiel de générer des revenus importants pour Clyra. Le PDG Dennis P. Calvert a souligné l'investissement de la société pour répondre aux spécifications des clients et commercialiser les produits, sans toutefois fournir de calendrier précis ni de prévisions de volume de ventes.
BioLargo (OTCQX:BLGO) gab bekannt, dass seine Tochtergesellschaft Clyra Medical Technologies mehrere Vertriebsvereinbarungen für ihre Medizinprodukte auf nationalen und internationalen Märkten abgeschlossen hat. Obwohl diese Vereinbarungen keine Mindestabnahmemengen vorsehen, haben sie jeweils das Potenzial, erhebliche Umsätze für Clyra zu generieren. CEO Dennis P. Calvert hob die Investitionen des Unternehmens hervor, um Kundenspezifikationen zu erfüllen und Produkte auf den Markt zu bringen, ohne jedoch einen konkreten Zeitplan oder Absatzprognosen zu nennen.
- Expansion of distribution network through multiple agreements
- Potential for material revenue generation from each agreement
- Successfully met client specifications for product requirements
- No minimum purchase requirements in the agreements
- Uncertain timeline for revenue generation
- No specific sales volume predictions provided
WESTMINSTER, CA / ACCESS Newswire / May 13, 2025 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and health challenges, today announced that its subsidiary Clyra Medical Technologies, Inc. ("Clyra") has entered into a series of agreements to advance the sales and distribution of its medical products in the U.S. and abroad. Although none of the agreements require minimum product purchases, each agreement has the potential to generate material revenue for Clyra.
Dennis P. Calvert, CEO at BioLargo commented, "These agreements reflect the significant time, energy and resources Clyra has invested to meet client specifications and bring products to market. While no prediction can be made as to when the agreements will result in product sales, or the volume of sales, we believe each could be important as Clyra grows. We look forward to announcing more developments as the products go to market."
About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. BioLargo is the majority owner of Clyra Medical Technologies, Inc. (www.ClyraMedical.com), a company focused on commercializing medical products based on BioLargo and Clyra's proprietary technologies.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
SOURCE: BioLargo, Inc
View the original press release on ACCESS Newswire
FAQ
What distribution agreements did BioLargo (BLGO) announce in May 2025?
Are there minimum purchase requirements in BLGO's Clyra Medical distribution agreements?
What is the potential revenue impact of Clyra Medical's new distribution agreements?
Who is the CEO of BioLargo (BLGO)?
